KGN Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The KGN cell line is a human ovarian granulosa tumor cell line derived from a patient with ovarian cancer and immortalized for use in various research studies. It maintains the functional characteristics of granulosa cells, including hormone synthesis, making it a valuable model for examining granulosa cell functions, hormonal regulation, and ovarian pathology. KGN cells have been utilized to investigate the molecular mechanisms underlying reproductive and endocrine disorders such as polycystic ovary syndrome (PCOS). They are particularly noted for their response to polyunsaturated fatty acids like arachidonic acid (AA), which can induce oxidative stress (OS) and impact mitochondrial function. Research has shown that exposure to AA in KGN cells elevates levels of oxidative markers such as reactive oxygen species (ROS) and malondialdehyde (MDA), reduces total antioxidant capacity, and impairs mitochondrial activity, leading to cell apoptosis. This process is associated with the upregulation of growth differentiation factor 15 (GDF15), which appears to serve a protective role against cellular damage induced by oxidative stress. Additionally, KGN cells are sensitive to ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation and oxidative stress. Studies highlight that iron uptake mediated through the transferrin receptor can promote ROS production and contribute to this pathway. Furthermore, KGN cells have been used to study the impact of microRNAs on cell function, as miR-93-5p has been identified as a factor promoting apoptosis and ferroptosis through the NF-κB signaling pathway, linking miRNA regulation to granulosa cell dysfunction in PCOS. These capabilities make KGN cells a significant model for advancing understanding of ovarian pathophysiology and exploring potential therapeutic targets. |
|---|---|
| Organism | Human |
| Tissue | Ovary, ovarian follicle, granulosa cell layer |
| Disease | Ovarian granulosa cell tumor |
Characteristics
| Age | 63 years |
|---|---|
| Gender | Female |
| Ethnicity | Japanese |
| Morphology | Fibroblast-like |
| Growth properties | Adherent |
Regulatory Data
| Citation | KGN (Cytion catalog number 305446) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0375 |
Biomolecular Data
| Mutational profile | Mutation: FOXL2, p.Cys134Trp (c.402C>G), heterozygous |
|---|
Handling
| Culture Medium | DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305446-280725 | Certificate of Analysis | 22. Oct. 2025 | 305446 |